Oculis Holding AG (OCS) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $28.40: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.67; Below-average business quality. (Note: Risk dimension 4.4/10 and A.R:R 4.3:1 are different metrics that happen to read the same number here.)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach... Read more
Sell if holding. Engine safety override at $28.40: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.67; Below-average business quality. (Note: Risk dimension 4.4/10 and A.R:R 4.3:1 are different metrics that happen to read the same number here.) Chart setup: RSI 55 mid-range, Bollinger mid-band. Score 4.6/10, moderate confidence.
Passes 9/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.80, news boost analyst cluster(3), earnings proximity 80d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent Developments — Oculis Holding AG
Latest news
- JP Morgan Maintains Overweight on Oculis Holding, Raises Price Target to $42 — benzinga May 18, 2026 positive
- Needham Maintains Buy on Oculis Holding, Raises Price Target to $46 — benzinga May 12, 2026 positive
- HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $47 — benzinga May 12, 2026 positive
- Oculis Holding Q1 EPS $(0.63) Misses $(0.49) Estimate, Sales $266.845K Miss $320.000K Estimate — benzinga May 11, 2026 negative
- Oculis Receives FDA Special Protocol Assessment Agreement For Privosegtor PIONEER-1 Registrational Trial In Optic Neurit — benzinga May 7, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·2 ceiling hits
Revenue shrinking — -26.7% YoY. Growth thesis broken unless recovery story develops.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $28.40: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.67; Below-average business quality. (Note: Risk dimension 4.4/10 and A.R:R 4.3:1 are different metrics that happen to read the same number here.) Chart setup: RSI 55 mid-range, Bollinger mid-band. Prior stop was $26.11. Score 4.6/10, moderate confidence.
Take-profit target: $42.51 (+51.4% upside). Prior stop was $26.11. Stop-loss: $26.11.
Quality below floor (1.8 < 4.0).
Oculis Holding AG trades at a P/E of N/A (forward -14.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
15 analysts cover OCS with a consensus score of 4.3/5. Average price target: $49.
What does Oculis Holding AG do?Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic,...
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.